10.53 2.03 (23.88%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 12.55 ![]() |
1-year : | 14.66 ![]() |
Resists | First : | 10.75 ![]() |
Second : | 12.55 ![]() |
Pivot price | 7.81 ![]() |
|||
Supports | First : | 7.93 ![]() |
Second : | 6.19 |
MAs | MA(5) : | 8.53 ![]() |
MA(20) : | 7.67 ![]() |
MA(100) : | 6.95 ![]() |
MA(250) : | 7.99 ![]() |
|
MACD | MACD : | 0.4 ![]() |
Signal : | 0.2 ![]() |
%K %D | K(14,3) : | 96.9 ![]() |
D(3) : | 85 ![]() |
RSI | RSI(14): 76 ![]() |
|||
52-week | High : | 15.73 | Low : | 5.59 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RXRX ] has closed above the upper band by 33.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 79.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 10.76 - 10.8 | 10.8 - 10.85 |
Low: | 8.95 - 8.99 | 8.99 - 9.03 |
Close: | 10.45 - 10.53 | 10.53 - 10.6 |
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Sat, 15 Feb 2025
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 8.6% - What's Next? - MarketBeat
Sat, 15 Feb 2025
Why Recursion Pharmaceuticals Inc. (RXRX) Soared on Friday? - Yahoo Canada Finance
Fri, 14 Feb 2025
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 8.6% Higher - What's Next? - MarketBeat
Fri, 14 Feb 2025
Why Recursion Pharmaceuticals Stock Is Soaring Today - Nasdaq
Fri, 14 Feb 2025
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Still a Buy? - MarketBeat
Fri, 14 Feb 2025
Recursion Pharmaceuticals Needs A Clinical Breakthrough To Pique Interest (NASDAQ:RXRX) - Seeking Alpha
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 384 (M) |
Shares Float | 252 (M) |
Held by Insiders | 3.5 (%) |
Held by Institutions | 68.8 (%) |
Shares Short | 67,860 (K) |
Shares Short P.Month | 67,100 (K) |
EPS | -1.54 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 1.83 |
Profit Margin | 0 % |
Operating Margin | -377.2 % |
Return on Assets (ttm) | -36.5 % |
Return on Equity (ttm) | -78.5 % |
Qtrly Rev. Growth | 147.6 % |
Gross Profit (p.s.) | -0.69 |
Sales Per Share | 0.16 |
EBITDA (p.s.) | -0.95 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -318 (M) |
Levered Free Cash Flow | -186 (M) |
PE Ratio | -6.84 |
PEG Ratio | 0 |
Price to Book value | 5.75 |
Price to Sales | 61.99 |
Price to Cash Flow | -12.72 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |